The FDA has been cracking down on compounded GLP-1 medications, but this does not affect the gray market. As the community explains: "They cannot control the grey market. It is not going anywhere. This is talking about compounding pharmacies—we are not compounding pharmacies." If anything, regulatory pressure on compounding pharmacies has pushed more people toward the gray market.